Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Seattle Genetics, Astellas ally with Merck in trial collaboration

Executive Summary

Seattle Genetics Inc. and Astellas Pharma Inc. are teaming up with Merck & Co. Inc. in a trial collaboration to evaluate the combination of Seattle Genetics/Astellas' enfortumab vedotin and Merck’s Keytruda (pembrolizumab) in patients with previously untreated metastatic urothelial cancer.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Immuno-Oncology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Trial Collaborations
    • R&D (No Licensing)

Related Companies